Description

Buy Xgeva (Denosumab) For Sale USA

Xgeva is a monoclonal antibody. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage.

The Xgeva brand of denosumab is used to prevent bone fractures and other skeletal conditions in people with multiple myeloma, and in people with tumors that have spread to the bone.

Xgeva is also used to treat giant cell bone tumor in adults and teenagers with fully matured bone structure.

Xgeva is also used to treat high blood levels of calcium caused by cancer, when other medicines such as pamidronate or zoledronic acid (Zometa) have been used without success.

Xgeva was FDA-approved on June 1, 2010. Prolia is another brand of denosumab used to treat osteoporosis in postmenopausal women who have a high risk of bone fracture, and this was approved on the same date. Xgeva and Prolia have different dosages and uses and are not interchangeable (see Xgeva vs Prolia. How do they compare? for more information).

Wyost (denosumab-bbdz) is an interchangeable biosimilar to Xgeva that was FDA-approved on 5 March 2024. An interchangeable biosimilar is a biological product that can be substituted in the pharmacy for the reference biologic because there are no clinically meaningful differences in safety, purity, and potency.

Warnings

This medication guide provides information about the Xgeva brand of denosumab. Prolia is another brand of denosumab used to treat osteoporosis in postmenopausal women who have high risk of bone fracture.

Do not use denosumab if you are pregnant.

You should not receive Xgeva if you are allergic to denosumab, or if you have low levels of calcium in your blood (hypocalcemia).

Before you receive this medicine, tell your doctor if you have kidney disease or if you are on dialysis.

Some people using Xgeva have developed bone loss in the jaw, also called osteonecrosis of the jaw. Symptoms may include jaw pain, swelling, numbness, loose teeth, gum infection, or slow healing after injury or surgery involving the gums. You may be more likely to develop osteonecrosis of the jaw if you have cancer or have been treated with chemotherapy, radiation, or steroids. Other conditions associated with osteonecrosis of the jaw include blood clotting disorders, anemia (low red blood cells), and a pre-existing dental problem.

If you need to have any dental work (especially surgery), tell the dentist ahead of time that you are receiving Xgeva. You may need to stop using the medicine for a short time.

Before receiving Xgeva

You should not receive Xgeva if you are allergic to denosumab or if you have low levels of calcium in your blood (hypocalcemia).

While you are receiving Xgeva, you should not use Prolia, another brand of denosumab.

To make sure you can safely use this medicine, tell your doctor if you have kidney disease (or if you are on dialysis).

Xgeva may cause bone loss (osteonecrosis) in the jaw. Symptoms include jaw pain or numbness, red or swollen gums, loose teeth, or slow healing after dental work.

Osteonecrosis of the jaw may be more likely if you have cancer or received chemotherapy, radiation, or steroids. Other risk factors include blood clotting disorders, anemia (low red blood cells), and a pre-existing dental problem. Buy Xgeva (Denosumab) For Sale USA

Denosumab can harm an unborn baby. You may need to have a negative pregnancy test before starting this treatment. Use effective birth control while using this medicine, and for at least 5 months after your last dose.